John M Maris

List of Publications by Year
in descending order

336 papers	38,196 citations	2975 93 h-index	3487 182 g-index
367 all docs	367 docs citations	367 times ranked	33909 citing authors

#	Article	IF	Citations
1	DNMT3Aovergrowth syndrome is associated with the development of hematopoietic malignancies in children and young adults. Blood, 2022, 139, 461-464.	1.4	9
2	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	30.7	53
3	GPC2-CAR TÂcells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell, 2022, 40, 53-69.e9.	16.8	60
4	Identification of Mitochondrial DNA Variants Associated With Risk of Neuroblastoma. Journal of the National Cancer Institute, 2022, 114, 910-913.	6.3	4
5	Epigenetic state determines inflammatory sensing in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	21
6	Genetic analysis in African American children supports ancestry specific neuroblastoma susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.EPI-21-0782-A.2021.	2.5	1
7	Paraneoplastic myasthenia gravis and pemphigus associated with follicular dendritic cell sarcoma leading to cardiorespiratory collapse in a 7â€yearâ€old. Pediatric Blood and Cancer, 2022, 69, e29723.	1.5	2
8	Abstract LB188: Identification of intrinsic molecular vulnerabilities in inherited and treatment-related hypermutant patient-derived glioma cell line models. Cancer Research, 2022, 82, LB188-LB188.	0.9	0
9	Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Childrenâ€™s Oncology Group (COG) risk stratification.. Journal of Clinical Oncology, 2022, 40, 10013-10013.	1.6	0
10	Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.. Journal of Clinical Oncology, 2022, 40, 10041-10041.	1.6	0
11	Evaluation of the DLL3-targeting Antibodyâ€“Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma. Cancer Research Communications, 2022, 2, 616-623.	1.7	1
12	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 4107-4118.	1.6	11
13	Refining immunotherapeutic approaches to highâ€risk neuroblastoma based on tumor genomic profiles. Molecular Oncology, 2021, 15, 347-349.	4.6	0
14	PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma. ACS Pharmacology and Translational Science, 2021, 4, 344-351.	4.9	16
15	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research, 2021, 27, 2179-2189.	7.0	95
16	Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake. JCO Precision Oncology, 2021, 5, 275-285.	3.0	3
17	GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma. Cancer Research, 2021, 81, 2995-3007.	0.9	15
18	Mutations in the RAS/MAPK Pathway Drive Replication Repairâ€“Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discovery, 2021, 11, 1454-1467.	9.4	19

#	Article	IF	Citations
19	HACE1 blocks HIF1Î± accumulation under hypoxia in a RAC1 dependent manner. Oncogene, 2021, 40, 1988-2001.	5.9	5
20	The B7-H3â€"Targeting Antibodyâ€"Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clinical Cancer Research, 2021, 27, 2938-2946.	7.0	55
21	Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. Molecular Oncology, 2021, 15, 2156-2171.	4.6	11
22	Bromodomain and extra-terminalÂinhibitorsâ€"A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in childrenâ€"ACCELERATE. European Journal of Cancer, 2021, 146, 115-124.	2.8	10
23	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers, 2021, 13, 1807.	3.7	4
24	Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC).. Journal of Clinical Oncology, 2021, 39, 10037-10037.	1.6	2
25	IMMU-16. TARGETING GLYPICAN 2 (GPC2) ON PEDIATRIC MALIGNANT BRAIN TUMORS WITH MRNA CAR T CELLS. Neuro-Oncology, 2021, 23, i30-i30.	1.2	1
26	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	1.6	174
27	A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Reports Medicine, 2021, 2, 100344.	6.5	14
28	Abstract 3028: Integrative genomics reveals lncRNAs associated with pediatric cancer. , 2021, , .		1
29	Abstract 1493: Discovery and CAR T targeting of lineage-restricted neuroblastoma oncoproteins. , 2021, , .		0
30	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of Clinical Oncology, 2021, 39, 3506-3514.	1.6	38
31	Drugging the â€œUndruggableâ€•MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Research, 2021, 81, 1627-1632.	0.9	25
32	Stage 4S Neuroblastoma. American Journal of Surgical Pathology, 2021, 45, 1075-1081.	3.7	10
33	Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia, 2020, 34, 1202-1207.	7.2	61
34	PARP-1â€"Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma. Journal of Nuclear Medicine, 2020, 61, 850-856.	5.0	30
35	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183.	12.8	87
36	SAT-163 Status at 10 Years: Long-Term Follow-Up for a Phase 2a Study of High-Specific-Activity (HSA) I 131 Iobenguane in Patients (Pts) with Relapsed/Refractory High-Risk Neuroblastoma. Journal of the Endocrine Society, 2020, 4, .	0.2	2

#	Article	IF	Citations
37	Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma. Genome Research, 2020, 30, 1228-1242.	5.5	20
38	annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions. BMC Bioinformatics, 2020, 21, 577.	2.6	4
39	Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity. Cell Reports Medicine, 2020, 1, 100036.	6.5	65
40	Immune-Based Approaches for the Treatment of Pediatric Malignancies. Annual Review of Cancer Biology, 2020, 4, 353-370.	4.5	7
41	Crossing Oceans: Preclinical Collaboration to Improve Pediatric Drug Development. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 409-416.	3.8	1
42	Immunogenicity and Immune Silence in Human Cancer. Frontiers in Immunology, 2020, 11, 69.	4.8	22
43	CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma. Frontiers in Oncology, 2020, 10, 302.	2.8	13
44	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer, 2020, 136, 52-68.	2.8	42
45	Mitochondrial DNA Haplogroups and Susceptibility to Neuroblastoma. Journal of the National Cancer Institute, 2020, 112, 1259-1266.	6.3	10
46	Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. Pediatric Blood and Cancer, 2020, 67, e28098.	1.5	13
47	Tattonâ€Brownâ€Rahman syndrome: Six individuals with novel features. American Journal of Medical Genetics, Part A, 2020, 182, 673-680.	1.2	11
48	Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations. Nature Communications, 2020, 11, 255.	12.8	48
49	Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clinical Cancer Research, 2020, 26, 1213-1219.	7.0	38
50	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 2160-2169.	1.6	98
51	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine, 2020, 26, 720-731.	30.7	141
52	LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase. Neoplasia, 2020, 22, 231-241.	5.3	21
53	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	28.9	334
54	Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28267.	1.5	16

#	Article	IF	Citations
55	High throughput pMHC-I tetramer library production using chaperone-mediated peptide exchange. Nature Communications, 2020, 11, 1909.	12.8	48
56	Epigenomic profiling of neuroblastoma cell lines. Scientific Data, 2020, 7, 116.	5.3	32
57	Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Research, 2020, 80, 2663-2675.	0.9	55
58	Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.. Journal of Clinical Oncology, 2020, 38, 10504-10504.	1.6	20
59	Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients.. Journal of Clinical Oncology, 2020, 38, e13666-e13666.	1.6	1
60	Image-guided core needle biopsy for relapsed and refractory neuroblastoma: A focus on sample adequacy for genetic sequencing.. Journal of Clinical Oncology, 2020, 38, e22521-e22521.	1.6	1
61	A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.. Journal of Clinical Oncology, 2020, 38, TPS10561-TPS10561.	1.6	2
62	Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Childrenâ€™s Oncology Group (COG) ANBL0032.. Journal of Clinical Oncology, 2020, 38, 10523-10523.	1.6	0
63	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Childrenâ€™s Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 3243-3255.	1.6	61
64	Neuroblastoma in relation to joint effects of vitamin A and maternal and offspring variants in vitamin A-related genes: A report of the Childrenâ€™s Oncology Group. Cancer Epidemiology, 2019, 61, 165-171.	1.9	6
65	ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. Cancer Cell, 2019, 36, 512-527.e9.	16.8	44
66	Immunotherapy for pediatric brain tumors: past and present. Neuro-Oncology, 2019, 21, 1226-1238.	1.2	32
67	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports, 2019, 29, 1675-1689.e9.	6.4	103
68	YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling. Cancer Research, 2019, 79, 6204-6214.	0.9	46
69	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clinical Cancer Research, 2019, 25, 6044-6051.	7.0	20
70	Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma. JAMA - Journal of the American Medical Association, 2019, 322, 746.	7.4	220
71	Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease. Genes, 2019, 10, 663.	2.4	14
72	Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Medicine, 2019, 11, 32.	8.2	79

#	Article	IF	Citations
73	Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models. Molecular Cancer Therapeutics, 2019, 18, 1195-1204.	4.1	36
74	IMMU-04. DEVELOPMENT OF GPC2-DIRECTED CHIMERIC ANTIGEN RECEPTOR THERAPY FOR PEDIATRIC BRAIN TUMORS WITH IN VITRO TRANSCRIBED mRNA. Neuro-Oncology, 2019, 21, ii93-ii93.	1.2	0
75	Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 401-408.	0.8	19
76	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Childrenâ€™s Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 115-124.	1.6	45
77	PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level. Journal of Experimental and Clinical Cancer Research, 2019, 38, 69.	8.6	19
78	Dr. Giulio J. Dâ€™Angio (1922â€“2018). Pediatric Research, 2019, 85, 752-753.	2.3	1
79	When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors. Cancer Cell, 2019, 36, 575-576.	16.8	10
80	Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. , 2019, 7, 344.		45
81	ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. Nature Communications, 2019, 10, 5622.	12.8	56
82	Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. Clinical Cancer Research, 2019, 25, 2278-2289.	7.0	57
83	The challenge of defining â€œultraâ€•highâ€•riskâ€•neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27556.	1.5	43
84	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clinical Cancer Research, 2019, 25, 2560-2574.	7.0	369
85	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.. Journal of Clinical Oncology, 2019, 37, 10012-10012.	1.6	1
86	Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts. , 2019, , .		1
87	Cross-Cohort Analysis Identifies a TEAD4â€“MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discovery, 2018, 8, 582-599.	9.4	119
88	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73
89	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature, 2018, 555, 371-376.	27.8	649
90	Rare MYC-amplified Neuroblastoma With Large Cell Histology. Pediatric and Developmental Pathology, 2018, 21, 461-466.	1.0	11

#	Article	IF	Citations
91	QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. Bioinformatics, 2018, 34, 1808-1816.	4.1	20
92	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clinical Cancer Research, 2018, 24, 189-196.	7.0	45
93	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. The Lancet Child and Adolescent Health, 2018, 2, 25-34.	5.6	38
94	Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with highâ€risk neuroblastoma: A case series. Pediatric Blood and Cancer, 2018, 65, e26732.	1.5	21
95	TBIO-29. PedcBioPortal, A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES. Neuro-Oncology, 2018, 20, i186-i186.	1.2	0
96	MBRS-57. TARGETING METABOLIC ADAPTATION IN MYC/MYCN AMPLIFIED PEDIATRIC MEDULLOBLASTOMA AND NEUROBLASTOMA. Neuro-Oncology, 2018, 20, i140-i140.	1.2	0
97	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma. Clinical Cancer Research, 2018, 24, 5673-5684.	7.0	92
98	A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations. Frontiers in Immunology, 2018, 9, 99.	4.8	35
99	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Childrenâ€™s Oncology Group Study ANBL0931. Frontiers in Immunology, 2018, 9, 1355.	4.8	66
100	Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clinical Cancer Research, 2018, 24, 6142-6149.	7.0	55
101	Fine mapping of 2q35 highâ€risk neuroblastoma locus reveals independent functional risk variants and suggests fullâ€length BARD1 as tumorâ€suppressor. International Journal of Cancer, 2018, 143, 2828-2837.	5.1	54
102	Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2018, 36, 10508-10508.	1.6	3
103	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the childrenâ€™s oncology group. Oncotarget, 2018, 9, 6416-6432.	1.8	31
104	Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Research, 2017, 77, 509-519.	0.9	75
105	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases. JAMA Oncology, 2017, 3, 636.	7.1	376
106	Genetic susceptibility to neuroblastoma. Current Opinion in Genetics and Development, 2017, 42, 81-90.	3.3	75
107	Irinotecanâ€“temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2017, 18, 946-957.	10.7	205
108	MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. Cell Death and Differentiation, 2017, 24, 1564-1576.	11.2	24

#	Article	IF	Citations
109	Assessment of programmed deathâ€ligand 1 expression and tumorâ€associated immune cells in pediatric cancer tissues. Cancer, 2017, 123, 3807-3815.	4.1	135
110	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2017, 64, e26545.	1.5	30
111	Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Scientific Data, 2017, 4, 170033.	5.3	113
112	Dexmedetomidine does not interfere with metaâ€iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations. Pediatric Blood and Cancer, 2017, 64, e26268.	1.5	2
113	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	28.9	596
114	LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell, 2017, 32, 310-323.e5.	16.8	80
115	Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk. Nature Communications, 2017, 8, 569.	12.8	22
116	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell, 2017, 32, 295-309.e12.	16.8	148
117	Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. Journal of the National Cancer Institute, 2017, 109, .	6.3	20
118	11q deletion in neuroblastoma: a review of biological and clinical implications. Molecular Cancer, 2017, 16, 114.	19.2	96
119	Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2017, 64, e26304.	1.5	20
120	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2017, 64, e26263.	1.5	15
121	Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clinical Cancer Research, 2017, 23, 1785-1796.	7.0	66
122	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology, 2017, 35, 2580-2587.	1.6	219
123	A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS2596-TPS2596.	1.6	13
124	Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. PLoS ONE, 2016, 11, e0161039.	2.5	21
125	Initial Testing (Stage 1) of MKâ€8242â€"A Novel MDM2 Inhibitorâ€"by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2016, 63, 1744-1752.	1.5	27
126	A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatric Blood and Cancer, 2016, 63, 1349-1356.	1.5	66

#	Article	IF	Citations
127	A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Childrenâ€™s Oncology Group. Cancer Causes and Control, 2016, 27, 1209-1218.	1.8	8
128	Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer, 2016, 122, 20-33.	4.1	175
129	Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine. European Journal of Cancer, 2016, 66, 144-152.	2.8	22
130	Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Research, 2016, 76, 5798-5809.	0.9	52
131	Neuroblastoma. Nature Reviews Disease Primers, 2016, 2, 16078.	30.5	907
132	Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPTâ€330): A report from the pediatric preclinical testing program. Pediatric Blood and Cancer, 2016, 63, 276-286.	1.5	28
133	Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2016, 63, 443-450.	1.5	0
134	MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Letters, 2016, 371, 214-224.	7.2	46
135	Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes. MAbs, 2016, 8, 799-810.	5.2	30
136	Imaging genomics in cancer research: limitations and promises. British Journal of Radiology, 2016, 89, 20151030.	2.2	90
137	Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to) Tj ETQq1 1 0.784314 rgBT /Over	1.7	19
138	Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10502-10502.	1.6	4
139	Assessment of PD-L1 expression and tumor associated immune cells in pediatric cancer tissues.. Journal of Clinical Oncology, 2016, 34, 11542-11542.	1.6	3
140	Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial.. Journal of Clinical Oncology, 2016, 34, e14014-e14014.	1.6	1
141	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	1.6	17
142	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	1.6	31
143	Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. PLoS Genetics, 2016, 12, e1006501.	3.5	98
144	Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS ONE, 2016, 11, e0147682.	2.5	32

#	Article	IF	Citations
145	Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10526-10526.	1.6	0
146	Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.. Journal of Clinical Oncology, 2016, 34, 10556-10556.	1.6	0
147	Initial testing (stage 1) of the antiâ€microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2015, 62, 1897-1905.	1.5	14
148	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatric Blood and Cancer, 2015, 62, 91-98.	1.5	65
149	Initial testing (stage 1) of the tubulin binding agent nanoparticle albuminâ€bound (nab) paclitaxel (Abraxane^{Â®}) by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 2015, 62, 1214-1221.	1.5	29
150	Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome. Pediatric Blood and Cancer, 2015, 62, 2007-2010.	1.5	12
151	Pilot study of intravenous melphalan combined with continuous infusion L-S,R -buthionine sulfoximine for children with recurrent neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 1739-1746.	1.5	31
152	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clinical Cancer Research, 2015, 21, 819-832.	7.0	100
153	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
154	CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Research, 2015, 75, 3155-3166.	0.9	132
155	Identifying Rare Events in Rare Diseases. Clinical Cancer Research, 2015, 21, 1782-1785.	7.0	9
156	131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biology of Blood and Marrow Transplantation, 2015, 21, 673-681.	2.0	79
157	A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. Cancer Cell, 2015, 28, 599-609.	16.8	99
158	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery, 2015, 5, 1282-1295.	9.4	997
159	Improving Patient Outcomes With Cancer Genomics. JAMA - Journal of the American Medical Association, 2015, 314, 881.	7.4	8
160	G-CSF Is a Cancer Stem Cellâ€“Specific Growth Factorâ€”Letter. Cancer Research, 2015, 75, 3991-3991.	0.9	5
161	MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. Cell Metabolism, 2015, 22, 1009-1019.	16.2	217
162	Defining Why Cancer Develops in Children. New England Journal of Medicine, 2015, 373, 2373-2375.	27.0	8

#	Article	IF	Citations
163	Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature, 2015, 528, 418-421.	27.8	263
164	Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget, 2015, 6, 18558-18576.	1.8	26
165	Abstract IA04: Neuroblastoma as a paradigm of MYC(N) driven cancers. , 2015, , .		0
166	Abstract B34: Antitumor activity and sensitivity evaluation of novel BET inhibitors in neuroblastoma. , 2015, , .		0
167	Abstract A37: Immunohistochemical detection of MYCN protein and MYC protein identifies highly aggressive neuroblastomas. , 2015, , .		0
168	Common Genetic Variants in NEFL Influence Gene Expression and Neuroblastoma Risk. Cancer Research, 2014, 74, 6913-6924.	0.9	74
169	Time to disease progression in children with relapsed or refractory neuroblastoma treated with <scp>ABT</scp>â€751: A report from the Children's Oncology Group (ANBL0621). Pediatric Blood and Cancer, 2014, 61, 990-996.	1.5	16
170	The promises and pitfalls of genetic epidemiologic approaches to pediatric cancers: Lessons from MDM2. Pediatric Blood and Cancer, 2014, 61, 1717-1718.	1.5	0
171	Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1972-1979.	1.5	7
172	Inactivation of SMC2 shows a synergistic lethal response inMYCN-amplified neuroblastoma cells. Cell Cycle, 2014, 13, 1115-1131.	2.6	30
173	Reply to N.-K.V. Cheung et al. Journal of Clinical Oncology, 2014, 32, 4174-4175.	1.6	6
174	Initial testing (stage 1) of the poloâ€like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2014, 61, 158-164.	1.5	46
175	Rare Variants in TP53 and Susceptibility to Neuroblastoma. Journal of the National Cancer Institute, 2014, 106, dju047.	6.3	100
176	Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Childrenâ€™s Oncology Group study ANBL0531.. Journal of Clinical Oncology, 2014, 32, 10006-10006.	1.6	6
177	A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study.. Journal of Clinical Oncology, 2014, 32, 10044-10044.	1.6	8
178	Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 633-641.	1.5	55
179	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncology, The, 2013, 14, 472-480.	10.7	614
180	Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatric Blood and Cancer, 2013, 60, 985-993.	1.5	285

#	Article	IF	Citations
181	Mitogenâ€activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromereâ€associated protein E inhibition. International Journal of Cancer, 2013, 132, E149-57.	5.1	16
182	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 999-1008.	10.7	246
183	Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 1325-1332.	1.5	77
184	The genetic landscape of high-risk neuroblastoma. Nature Genetics, 2013, 45, 279-284.	21.4	990
185	Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Childrenâ€™s Oncology Group. Journal of Nuclear Medicine, 2013, 54, 541-548.	5.0	169
186	Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clinical Cancer Research, 2013, 19, 6173-6182.	7.0	323
187	Cell culture andDrosophilamodel systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. DMM Disease Models and Mechanisms, 2013, 6, 373-82.	2.4	59
188	Targeting MYCN: A Good BET for Improving Neuroblastoma Therapy?. Cancer Discovery, 2013, 3, 255-257.	9.4	17
189	Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma. Cancer Research, 2013, 73, 776-784.	0.9	105
190	Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis, 2013, 34, 605-611.	2.8	95
191	Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. Cancer, 2013, 119, 3718-3726.	4.1	67
192	Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 1860-1867.	1.5	27
193	Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium. Pediatric Blood and Cancer, 2013, 60, 1801-1808.	1.5	72
194	Replication of Neuroblastoma SNP Association at the BARD1 Locus in African-Americans. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 658-663.	2.5	54
195	Dose Escalation Study of No-Carrier-Added ¹³¹I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. Journal of Nuclear Medicine, 2012, 53, 1155-1163.	5.0	64
196	Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study. Clinical Cancer Research, 2012, 18, 6058-6064.	7.0	110
197	Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival. Journal of the National Cancer Institute, 2012, 105, 302-309.	6.3	30
198	Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity. Cancer Research, 2012, 72, 2068-2078.	0.9	97

#	Article	IF	Citations
199	Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. Clinical Cancer Research, 2012, 18, 2679-2686.	7.0	69
200	Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. International Journal of Molecular Imaging, 2012, 2012, 1-8.	1.3	46
201	A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants. Annals of Surgery, 2012, 256, 573-580.	4.2	152
202	ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation. Cancer Cell, 2012, 22, 631-644.	16.8	309
203	Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nature Genetics, 2012, 44, 1126-1130.	21.4	231
204	New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome. Clinical Cancer Research, 2012, 18, 2423-2428.	7.0	70
205	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clinical Cancer Research, 2012, 18, 2012-2023.	7.0	59
206	Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641. Journal of Clinical Oncology, 2012, 30, 1842-1848.	1.6	174
207	Combination testing (Stage 2) of the Antiâ€IGFâ€1 receptor antibody IMCâ€A12 with rapamycin by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 729-735.	1.5	44
208	Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 566-571.	1.5	26
209	Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 636-639.	1.5	73
210	Initial testing of the CENPâ€E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 916-923.	1.5	39
211	Initial testing (stage 1) of SGIâ€1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 749-752.	1.5	20
212	Outcome analysis of non-high-risk neuroblastoma patients enrolled on Childrenâ€™s Oncology Group trials P9641 and A3961.. Journal of Clinical Oncology, 2012, 30, 9533-9533.	1.6	0
213	Relationship of divergent ancestral genetic variation on chromosome 6p22 and racial disparities in survival in neuroblastoma.. Journal of Clinical Oncology, 2012, 30, 9516-9516.	1.6	0
214	Pharmacokinetics (PK) of the chimericÂanti-G_{D2} antibody, ch14.18, in children with high-risk neuroblastoma.. Journal of Clinical Oncology, 2012, 30, 9576-9576.	1.6	0
215	Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci. PLoS Genetics, 2011, 7, e1002026.	3.5	141
216	Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature, 2011, 469, 216-220.	27.8	276

#	Article	IF	Citations
217	Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemotherapy and Pharmacology, 2011, 68, 1057-1065.	2.3	76
218	Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 1291-1304.	2.3	88
219	Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 1469-1475.	2.3	16
220	Initial testing (stage 1) of the IGFâ€1 receptor inhibitor BMSâ€754807 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2011, 56, 595-603.	1.5	67
221	Thyroid and hepatic function after highâ€dose ¹³¹Iâ€metaiodobenzylguanidine (¹³¹Iâ€MIBG) therapy for neuroblastoma. Pediatric Blood and Cancer, 2011, 56, 191-201.	1.5	55
222	Safety and efficacy of tandem ¹³¹Iâ€metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatric Blood and Cancer, 2011, 57, 1124-1129.	1.5	53
223	Genome-Wide Linkage Analysis to Identify Genetic Modifiers of <i>ALK</i> Mutation Penetrance in Familial Neuroblastoma. Human Heredity, 2011, 71, 135-139.	0.8	27
224	Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma. Science Translational Medicine, 2011, 3, 108ra114.	12.4	199
225	RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3336-3341.	7.1	227
226	Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 208-213.	1.6	127
227	Optimal false discovery rate control for dependent data. Statistics and Its Interface, 2011, 4, 417-430.	0.3	22
228	MEKing Retinoids Work Better. Cancer Cell, 2010, 18, 103-105.	16.8	2
229	Initial testing of topotecan by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 54, 707-715.	1.5	37
230	Initial testing of a monoclonal antibody (IMCâ€A12) against IGFâ€1R by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 54, 921-926.	1.5	89
231	Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 2010, 55, 26-34.	1.5	195
232	Initial testing of the replication competent Seneca Valley virus (NTXâ€010) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 295-303.	1.5	70
233	Initial testing (stage 1) of AZD6244 (ARRYâ€142886) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 668-677.	1.5	94
234	Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 1126-1133.	1.5	51

#	Article	IF	Citations
235	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. Molecular Cancer Therapeutics, 2010, 9, 101-112.	4.1	89
236	Genotypes of NK Cell KIR Receptors, Their Ligands, and FcÎ³ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy. Cancer Research, 2010, 70, 9554-9561.	0.9	163
237	Serial Transcriptome Analysis and Cross-Species Integration Identifies Centromere-Associated Protein E as a Novel Neuroblastoma Target. Cancer Research, 2010, 70, 2749-2758.	0.9	45
238	Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma. Clinical Cancer Research, 2010, 16, 1478-1485.	7.0	56
239	Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1Î±. Cancer Research, 2010, 70, 10351-10361.	0.9	132
240	Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study. Journal of Clinical Oncology, 2010, 28, 4969-4975.	1.6	220
241	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. New England Journal of Medicine, 2010, 363, 1313-1323.	27.0	253
242	Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. New England Journal of Medicine, 2010, 363, 1324-1334.	27.0	1,460
243	Recent Advances in Neuroblastoma. New England Journal of Medicine, 2010, 362, 2202-2211.	27.0	1,597
244	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. Clinical Cancer Research, 2010, 16, 1532-1541.	7.0	86
245	A hidden Markov random field model for genome-wide association studies. Biostatistics, 2010, 11, 139-150.	1.5	41
246	Molecular Therapy for Neuroblastoma. , 2010, , 351-371.		0
247	Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome Research, 2009, 19, 276-283.	5.5	69
248	Iodine-131â€"Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study. Journal of Clinical Oncology, 2009, 27, 1020-1025.	1.6	110
249	Inhibition of ALK Signaling for Cancer Therapy. Clinical Cancer Research, 2009, 15, 5609-5614.	7.0	149
250	Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study. Journal of Clinical Oncology, 2009, 27, 1290-1296.	1.6	69
251	Comparison of Iodine-123 Metaiodobenzylguanidine (MIBG) Scan and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography to Evaluate Response After Iodine-131 MIBG Therapy for Relapsed Neuroblastoma. Journal of Clinical Oncology, 2009, 27, 5343-5349.	1.6	95
252	Unholy Matrimony: Aurora A and N-Myc as Malignant Partners in Neuroblastoma. Cancer Cell, 2009, 15, 5-6.	16.8	19

#	Article	IF	Citations
253	Outcome of highâ€risk stage 3 neuroblastoma with myeloablative therapy and 13â€cisâ€retinoic acid: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2009, 52, 44-50.	1.5	51
254	Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2009, 53, 505-508.	1.5	54
255	Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatric Blood and Cancer, 2009, 53, 563-569.	1.5	79
256	Copy number variation at 1q21.1 associated with neuroblastoma. Nature, 2009, 459, 987-991.	27.8	329
257	Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nature Genetics, 2009, 41, 718-723.	21.4	266
258	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 37-45.	1.5	112
259	Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 581-587.	1.5	116
260	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 799-805.	1.5	162
261	Initial testing of dasatinib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 1198-1206.	1.5	69
262	Initial testing (stage 1) of the BH3 mimetic ABTâ€263 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 1181-1189.	1.5	108
263	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGFâ€1 receptor by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 1190-1197.	1.5	168
264	Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status. Pediatric Blood and Cancer, 2008, 51, 10-16.	1.5	37
265	Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 51, 42-48.	1.5	88
266	Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 2008, 455, 930-935.	27.8	1,207
267	Screening for neuroblastoma: a resurrected idea?. Lancet, The, 2008, 371, 1142-1143.	13.7	19
268	Molecular Characterization of the Pediatric Preclinical Testing Panel. Clinical Cancer Research, 2008, 14, 4572-4583.	7.0	116
269	High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14094-14099.	7.1	149
270	The kinesin KIF1BÎ² acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes and Development, 2008, 22, 884-893.	5.9	293

#	Article	IF	Citations
271	A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. Clinical Cancer Research, 2008, 14, 1111-1115.	7.0	45
272	A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene. Molecular Cancer Research, 2008, 6, 735-742.	3.4	298
273	Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Research, 2008, 36, e126-e126.	14.5	297
274	Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma. New England Journal of Medicine, 2008, 358, 2585-2593.	27.0	271
275	Effect of sleep stage on breathing in children with central hypoventilation. Journal of Applied Physiology, 2008, 105, 44-53.	2.5	55
276	Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma. Clinical Cancer Research, 2007, 13, 3499-3506.	7.0	35
277	Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma. Journal of Clinical Oncology, 2007, 25, 1054-1060.	1.6	228
278	Neuroblastoma. Lancet, The, 2007, 369, 2106-2120.	13.7	1,856
279	Genome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays. PLoS ONE, 2007, 2, e255.	2.5	105
280	Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes and Cancer, 2007, 46, 936-949.	2.8	101
281	The pediatric preclinical testing program: Description of models and early testing results. Pediatric Blood and Cancer, 2007, 49, 928-940.	1.5	430
282	Pediatric Horner Syndrome: Etiologies and Roles of Imaging and Urine Studies to Detect Neuroblastoma and Other Responsible Mass Lesions. American Journal of Ophthalmology, 2006, 142, 651-659.e2.	3.3	138
283	Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatric Blood and Cancer, 2006, 47, 865-874.	1.5	79
284	Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma. Journal of Clinical Oncology, 2006, 24, 5725-5734.	1.6	84
285	STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Research, 2006, 16, 1149-1158.	5.5	152
286	The H+-Linked Monocarboxylate Transporter (MCT1/SLC16A1): A Potential Therapeutic Target for High-Risk Neuroblastoma. Molecular Pharmacology, 2006, 70, 2108-2115.	2.3	155
287	High-Resolution Analysis of Chromosomal Breakpoints and Genomic Instability Identifies PTPRD as a Candidate Tumor Suppressor Gene in Neuroblastoma. Cancer Research, 2006, 66, 3673-3680.	0.9	121
288	Phase I Dose Escalation of Iodine-131â€"Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study. Journal of Clinical Oncology, 2006, 24, 500-506.	1.6	170

#	Article	IF	Citations
289	Integrative Genomics Identifies Distinct Molecular Classes of Neuroblastoma and Shows That Multiple Genes Are Targeted by Regional Alterations in DNA Copy Number. Cancer Research, 2006, 66, 6050-6062.	0.9	178
290	The biologic basis for neuroblastoma heterogeneity and risk stratification. Current Opinion in Pediatrics, 2005, 17, 7-13.	2.0	176
291	Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene, 2005, 24, 2684-2694.	5.9	147
292	Highâ€resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes and Cancer, 2005, 43, 390-403.	2.8	92
293	Tumor response and toxicity with multiple infusions of high dose131I-MIBG for refractory neuroblastoma. Pediatric Blood and Cancer, 2005, 44, 232-239.	1.5	81
294	How doesMYCN amplification make neuroblastomas behave aggressively? Still more questions than answers. Pediatric Blood and Cancer, 2005, 45, 869-870.	1.5	5
295	Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6466-6473.	1.6	135
296	Desmoplastic Small Round Cell Tumor in the Abdomen and Pelvis: Report of CT Findings in 11 Affected Children and Young Adults. American Journal of Roentgenology, 2005, 184, 1910-1914.	2.2	66
297	Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study. Journal of Clinical Oncology, 2005, 23, 6474-6480.	1.6	133
298	Proliferation of Human Neuroblastomas Mediated by the Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 9868-9875.	0.9	122
299	Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. Genome Research, 2005, 15, 1168-1176.	5.5	18
300	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. New England Journal of Medicine, 2005, 353, 2243-2253.	27.0	495
301	Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Letters, 2005, 228, 171-179.	7.2	41
302	Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era. Cancer Letters, 2005, 228, 83-90.	7.2	27
303	Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia. Cancer Research, 2004, 64, 8816-8820.	0.9	472
304	Hematologic Toxicity of High-Dose Iodine-131â€"Metaiodobenzylguanidine Therapy for Advanced Neuroblastoma. Journal of Clinical Oncology, 2004, 22, 2452-2460.	1.6	107
305	Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer, 2004, 11, 423-436.	3.1	299
306	Germline PHOX2B Mutation in Hereditary Neuroblastoma. American Journal of Human Genetics, 2004, 75, 727-730.	6.2	233

#	Article	IF	Citations
307	Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. Lancet Oncology, The, 2003, 4, 769-771.	10.7	38
308	Drosophila Rheb GTPase is required for cell cycle progression and cell growth. Journal of Cell Science, 2003, 116, 3601-3610.	2.0	147
309	Targeted Radiotherapy With Submyeloablative Doses of 131I-MIBG Is Effective for Disease Palliation in Highly Refractory Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2003, 25, 769-773.	0.6	56
310	Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clinical Cancer Research, 2003, 9, 3345-55.	7.0	46
311	Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Research, 2003, 63, 7861-9.	0.9	45
312	Focus on embryonal malignancies. Cancer Cell, 2002, 2, 447-450.	16.8	76
313	Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Research, 2002, 62, 6651-8.	0.9	65
314	Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 24-27.	1.0	48
315	Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 32-36.	1.0	63
316	Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 52-55.	1.0	16
317	Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 512-515.	1.0	25
318	Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Medical and Pediatric Oncology, 2000, 35, 526-530.	1.0	26
319	Deletion of 11q23 is a frequent event in the evolution ofMYCN single-copy high-risk neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 544-546.	1.0	37
320	Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Medical and Pediatric Oncology, 2000, 35, 673-676.	1.0	19
321	Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nature Genetics, 2000, 24, 266-270.	21.4	474
322	Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Childrenâ€™s Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 1888-1899.	1.6	146
323	A novel human processed gene, DAD-R, maps to 12p12 and is expressed in several organs. FEBS Letters, 2000, 473, 233-236.	2.8	1
324	Molecular Biology of Neuroblastoma. Journal of Clinical Oncology, 1999, 17, 2264-2264.	1.6	567

#	Article	IF	Citations
325	Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genetics, 1999, 23, 166-175.	21.4	1,036
326	Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene, 1999, 18, 4948-4957.	5.9	228
327	Familial neuroblastoma: A three-generation pedigree and a further association with Hirschsprung disease. , 1997, 28, 1-5.		40
328	Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. , 1997, 19, 176-184.		48
329	Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer, 1997, 79, 1438-1446.	4.1	3
330	Biology and Genetics of Human Neuroblastomas. The American Journal of Pediatric Hematology/oncology, 1997, 19, 93-101.	1.3	205
331	Physical Mapping and Genomic Structure of the HumanTNFR2Gene. Genomics, 1996, 35, 94-100.	2.9	65
332	Cerebral metabolic effects of neonatal seizures measured with in vivo31P NMR spectroscopy. Annals of Neurology, 1986, 20, 513-519.	5.3	114
333	P nuclear magnetic resonance spectroscopy: Noninvasive biochemical analysis of the ischemic extremity. Journal of Vascular Surgery, 1986, 3, 411-420.	1.1	83
334	³¹P Nuclear Magnetic Resonance Spectroscopic Investigation of Human Neuroblastoma in Situ. New England Journal of Medicine, 1985, 312, 1500-1505.	27.0	166
335	Diagnosis and therapeutic evaluation of a pediatric case of cardiomyopathy using phosphorus-31 nuclear magnetic resonance spectroscopy. Journal of the American College of Cardiology, 1985, 5, 745-749.	2.8	72
336	Molecular oncology of neuroblastoma. , 0, , 669-678.		0